AGC boasts 44,000L of biomanufacturing capacity on back of recent M&A

By Dan Stanton contact

- Last updated on GMT

Image: iStock/macgyverhh
Image: iStock/macgyverhh

Related tags: Biotechnology, Contract

After buying two CMOs, Japanese glassmaker AGC has made “a full-fledged launch” into the biologics manufacturing space and says it will consider further M&A opportunities.

Within the past four months, AGC Asahi Glass – a subsidiary of industrial glass, ceramic and chemical maker the AGC Group – has bought two biologics contract manufacturing organisations (CMOs).

In September, the firm launched itself into the space through the acquisition of Heidelberg, Germany-based Biomeva​, and weeks later signed an agreement to cement its stake in the industry through the ¥60bn ($516m) addition of Søborg, Denmark-headquartered CMC Biologics​.

Spokeswoman Tomoko Komazaki told us that with Danish manufacturing capacity and US sites in Seattle and Berkeley, the CMC Biologics deal meant AGC has made “a full-fledged launch into not only microbial but also mammalian CMO businesses in US and European markets which are fast growing and account for the main part of biopharmaceuticals business in the world.”

“Life science business is one of AGC’s strategically focusing business areas to achieve further growth,” ​she told us. “CMO business is an important part of AGC’s life science business and we have decided to expand into this field.”

AGC had some biomanufacturing capacity in its network, including a 4,500L fermentor at a site in Chiba, Japan, but once the CMC deal is complete – expected later this month – the Tokyo-headquartered firm will boast 10,000L of microbial capacity and 34,000L of mammalian capacity.

24,000L of the mammalian capacity will be single-use bioreactors, Komazaki said, including three Thermo Fisher 2,000L systems recently added​ by CMC Biologics in Denmark.

Komazaki also added the company will take into consideration any opportunities further M&A acquisitions in order to grow further its contract biomanufacturing business in the future.

Related news

Show more

Related products

show more

Strategies for Upstream Intensification

Strategies for Upstream Intensification

Take the Right Path Upstream with MilliporeSigma | 01-Sep-2020 | Technical / White Paper

The Facility of the Future represents a transformation in how biologics are developed and manufactured.

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 05-Aug-2020 | Technical / White Paper

Traditional methods for adventitious agent testing rely on biological amplification and detection, which can take several weeks. This time-consuming approach...

Related suppliers

Follow us

Products

View more

Webinars